Lava Therapeutics develops a bispecific antibody platform, Gammabody®, that engages Vγ9Vδ2 T cells to target and kill cancer cells while enhancing immune responses. This technology aims to improve tumor recognition and treatment efficacy, potentially leading to better patient survival outcomes.
Funding
$83M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NVFounders
Product
Problem
Current cancer therapies often fail to completely eradicate tumors and can cause significant side effects due to their lack of specificity. Many tumors evade detection by the immune system, leading to disease progression and poor patient outcomes.
Solution
Lava Therapeutics is developing a bispecific antibody platform, called Gammabody®, that enhances the body's immune response to cancer. Gammabody® therapeutics activate a specific subset of T cells, Vγ9Vδ2 T cells, directing them to recognize and kill cancer cells. This approach complements natural tumor recognition, selectively eliminates cancer cells, and triggers a broader immune response. Preclinical studies have demonstrated that Gammabody® drug candidates can potently and specifically activate Vγ9Vδ2 T cells, leading to the killing of patient-derived tumor cells.
Target Audience
The primary target audience includes patients with solid tumors and hematological malignancies who are not responding to existing therapies, as well as oncologists and hematologists seeking more effective and targeted treatment options.
Features
- Gammabody® platform generates bispecific gamma delta T cell engager therapeutics.
- Targets and activates Vγ9Vδ2 T cells, a unique and relatively abundant effector T cell subset.
- Designed to complement natural tumor recognition.
- Directs Vγ9Vδ2 T cells to the tumor microenvironment.
- Selectively kills cancer cells.
- Triggers a cascade of immune responses for durable effects.